An observational study in Obesity, sponsored by Scitech Produtos Medicos Ltda. Active, not recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.
Sponsored by Scitech Produtos Medicos Ltda · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 285 studies in Obesity with a site in Brazil — 41 open to participants now, 62 under way, 27 of them phase 3. Obesity · Brazil.
Among the 285 studies in Obesity with a site in Brazil, this one is the 10th largest by planned enrollment of the 32 observational ones that give a count, is one of 17 that started in 2023, is one of 32 observational ones, reaches primary completion later than 4 of the 61 other live ones, and was the 211th registered.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →41 of the 285 studies in Obesity with a site in Brazil are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Brazil, United States, China and 7 more countries
Ages 18+
Universidade Cesumar (UNICESUMAR) · Sites in Brazil
Ages 60+
AstraZeneca · Sites in Brazil, United States, Argentina and 8 more countries
Ages 18+
AstraZeneca · Sites in Brazil, United States, Argentina and 13 more countries
Ages 18+
Pfizer · Sites in Brazil, United States, Canada and 8 more countries
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
285 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 12 · Phase 3 55 · Phase 4 9
First in 2001; this study’s year is marked. 17 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 115 across 2,158 observational studies indexed under Obesity.
Median enrollment 60 across the 251 interventional studies, 55 across the 32 observational. Of the 163 that completed or were terminated, 15 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 285 have an industry lead sponsor. The 10 most frequent:
Scitech Produtos Medicos Ltda is the lead sponsor of 13 studies on the registry; none are open to participants now.
Scitech Produtos Medicos Ltda has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
18 of the studies in Obesity with a site in Brazil that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 285 studies in Obesity with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Post-marketing, observational study to evaluate the safety and performance of the ALTUS Powered Stapler in bariatric surgery of "real-world" patients.
Up to 300 patients who underwent sleeve, bypass or revisional bariatric surgery with the use of Altus Powered Stapler will be included in the study. The stapler should be used according to the Instructions for Use and according to the local practice.
The Altus Powered Stapler is used in open or laparoscopic surgeries and simultaneously cuts and staples soft tissues. In order to avoid great physical efforts by the physician and ensure excellent tissue suturing, the cutting and stapling mechanism is driven by the 12-volt battery that comes with the stapler.
Patients will be followed by 7, 30 and 90 days and 12 months after the procedure, as per the research center's standard routine.
Adults (18 years or older), who underwent bariatric surgery with the use of Altus Powered Stapler
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with grade II (with one or more associated comorbidities) and grade III obesity who went through sleeve, bypass and revisional bariatric surgery procedure with the use of Altus Powered Stapler
Device: Stapler
Stapling performed with ALTUS Powered Stapler
Safety - Conversion to open surgery
Number of conversions to open surgery during the index procedure
Time frame: Intraoperative
Safety - Number of reinterventions
Number of reinterventions within 1 week after the procedure
Time frame: Up to 1 week
Safety - Postoperative anastomotic leaking and intraluminal/intraperitoneal bleeding
Presence of complications of anastomotic leaking and intraluminal/intraperitoneal bleeding within 30 days after procedure
Time frame: 30 days
Safety- Fistula formation
Presence of fistula within 30 days after procedure
Time frame: 30 days
Safety - Stenosis
Detection of stenosis within 90 days after procedure
Time frame: 90 days
Performance - Procedure Success
Defined by completion of technique with the device for its intended use
Time frame: Intraoperative
Performance - Cicatrization of staple line
The absence of oozing/bleeding at the staple line
Time frame: 90 days
Post-operative change in weight
Defined by preoperative weight (kg) minus postoperative weight (kg) divided by ideal body weight (kg) at the end of 12 months.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Jul 2024, 13 months.
Of 45 industry-sponsored observational studies under Obesity, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 13 months is below that.
Counting every sponsor, half of 838 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Scitech Produtos Medicos Ltda